Hematopoietic Neoplasm
9
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Wearable Activity Tracking to Curb Hospitalizations
Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Effectiveness of Extraoral Photobiomodulation in Management of Oral Adverse Effects in Patients Undergoing HSCT
GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide
UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors